In addition to validating PIM1 as a resistance gene in NB cell lines, we sought to determine whether PIM1 induces resistance to ALK inhibition in another ALK-driven pediatric cancer, namely ALCL, since full-length ALK and NPM-ALK have been shown to activate common downstream pathways such as Ras/MAPK, PI3K/AKT and JAK/STAT50. The gene discussed is AKT1; the disease is neuroblastoma.